Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
2010
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
2015
Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach
2023 StandoutNobel
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
2002 Standout
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Skeletal Muscle Fatigue: Cellular Mechanisms
2008 Standout
Structural Requirements for Cannabinoid Receptor Probes
2005
Effects of Flavonoids and other Polyphenols on Inflammation
2011 Standout
Exercise-Induced Oxidative Stress: Cellular Mechanisms and Impact on Muscle Force Production
2008 Standout
In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans
2009
Prevention of VTE in Orthopedic Surgery Patients
2012 Standout
Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
2010 Standout
Do we need to consider inflammatory markers when we treat atherosclerotic disease?
2008
Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
2005
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
2005
Oral Anticoagulant Therapy
2012 Standout
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
2008
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Cell Biology of Ischemia/Reperfusion Injury
2012 Standout
The endocannabinoid system and its therapeutic exploitation
2004
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban
2013
Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats
2006
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti‐FXa assays
2014 StandoutNobel
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Novelty and Anxiolytic Drugs Dissociate Two Components of Hippocampal Theta in Behaving Rats
2013 StandoutNobel
The calpain 1–α‐actinin interaction
2003
Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model
2005
Mechanisms of water-holding capacity of meat: The role of postmortem biochemical and structural changes
2005 Standout
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
2006
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives
2021
CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents
2004
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1
2007
Physiology of Local Renin-Angiotensin Systems
2006 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
2013
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
2013
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
2009
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
2009 Standout
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor
2005
Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes
2004
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
2013 Standout
Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects
2007
The AT2 receptor—A matter of love and hate
2005
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
2008
Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
2010
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Recent advances in the trifluoromethylation methodology and new CF3-containing drugs
2014
Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor
2005
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
2006
The Calpain System
2003 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Natural Products as Sources of New Drugs over the Last 25 Years
2007 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)
2007
Synthesis, characterization, and biomedical assessment of novel bisimidazole–coumarin conjugates
2021 Standout
A Medicinal Chemist’s Guide to Molecular Interactions
2010 Standout
Regulation of Mammalian Autophagy in Physiology and Pathophysiology
2010 Standout
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Steffen Sandmann being referenced
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
2011
BAY 38–7271: A Novel Highly Selective and Highly Potent Cannabinoid Receptor Agonist for the Treatment of Traumatic Brain Injury
2003
Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs
2005
Activity profile of calpains I and II in chronically infarcted rat myocardium – influence of the calpain inhibitor CAL 9961
2002
Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction – effects of AT1 and AT2 receptor antagonists and ACE inhibitor
2001
Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats
1998
Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction
2019
Calcium channel blockade limits transcriptional, translational and functional up-regulation of the cardiac calpain system after myocardial infarction
2002
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats
2006
Differential effects of angiotensin AT1and AT2receptors on the expression, translation and function of the Na+-H+exchanger and Na+-HCO3−symporter in the rat heart after myocardial infarction
2001